Characterization of Novel Vaccine Targeting Follicle-Stimulating Hormone Receptor in Ovarian Cancer
Technical Report,15 May 2019,14 May 2020
WISTAR INST OF ANATOMY AND BIOLOGY PHILADELPHIA PA PHILADELPHIA United States
Pagination or Media Count:
Ovarian cancer initially responds well to treatment but returns in a high number of patients. The time after treatment when there is no disease provides a great opportunity for vaccinating against the tumor to prevent a return. An active immune system against the tumor has several advantages. It is associated with longer survival of ovarian cancer patients and it allows other immunotherapy i.e. Keytruda treatments to work. This immunotherapy has shown impressive results in other tumors as melanoma, but not in ovarian cancer because the immune system is poorly active against it. The follicle-stimulating hormone receptor FSHR is a protein expressed only in the ovaries which are removed by surgery and in 50-70 of ovarian cancer. We have generated a vaccine against FSHR and know that it activates the immune system in mice and improves survival in mouse ovarian cancer. Our objective is to improve survival of patients with ovarian cancer by 1 Testing the FSHR vaccine in mice with human immune system and against human ovarian tumors. 2 Combining the vaccine with immunotherapy to attempt to make ovarian cancer more sensitive to this revolutionary treatment.
- Medicine and Medical Research
- Anatomy and Physiology